Adaptive Biotechnologies prices upsized USD 300 million 0% convertible senior notes offering due 2031

Adaptive Biotechnologies

Adaptive Biotechnologies

ADPT

0.00
  • Adaptive Biotechnologies priced an upsized USD 300 million private offering of 0% convertible senior notes due 2031, raised from USD 250 million.
  • Deal includes a 13-day option for initial purchasers to buy up to an additional USD 45 million of notes.
  • Net proceeds estimated at USD 290.8 million, rising to about USD 334.5 million if the option is fully exercised.
  • Proceeds earmarked to repay the OrbiMed Purchase Agreement, fund a USD 22.3 million capped call, repurchase USD 25 million of stock.
  • Notes convert at 41.48 shares per USD 1,000, implying a USD 24.11 conversion price; settlement scheduled for June 22, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606170600PRIMZONEFULLFEED9748396) on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.